Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the sixth most common primary cancer with an unsatisfactory long-term survival. Gain of function mutations of PIK3CA occur in a subset of human HCC. Alpelisib, a selective PIK3CA inhibitor, has been approved by the FDA to treat PIK3CA mutant breast cancers. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hongwei, Chen, Kefei, Shang, Runze, Chen, Xinyan, Zhang, Yi, Song, Xinhua, Evert, Matthias, Zhong, Sheng, Li, Bo, Calvisi, Diego F., Chen, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501067/
https://www.ncbi.nlm.nih.gov/pubmed/34625531
http://dx.doi.org/10.1038/s41419-021-04206-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501067/
https://www.ncbi.nlm.nih.gov/pubmed/34625531
http://dx.doi.org/10.1038/s41419-021-04206-5

Ejemplares similares